Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22972810 | 1.00 | ALOX5 (0.32) | ALOX5MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL16292529 | 0.88 | ALOX5 (0.39) | ALOX5MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL343583 | 0.82 | ALOX5 (0.35) | ALOX5MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL343584 | 0.82 | ALOX5 (0.35) | ALOX5MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL16874912 | 0.81 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL482201 | 0.81 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL1498383 | 0.81 | ALOX5 (0.34) | ALOX5 | |
| SCHEMBL1192555 | 0.79 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL17440295 | 0.79 | ALOX5 (0.37) | ALOX5 | |
| SCHEMBL16337952 | 0.78 | L3MBTL3 (0.33) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273003-B2 | Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| EP-2295410-A1 | HDAC inhibitor | Chroma Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |